Treatment to Target Using Recombinant Interleukin‐1 Receptor Antagonist as First‐Line Monotherapy in New‐Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five‐Year Follow‐Up Study

OBJECTIVE: Systemic juvenile idiopathic arthritis (JIA) is a multifactorial autoinflammatory disease with a historically poor prognosis. With current treatment regimens, approximately half of patients still experience active disease after 1 year of therapy. This study was undertaken to evaluate a tr...

Descripción completa

Detalles Bibliográficos
Autores principales: ter Haar, Nienke M., van Dijkhuizen, E. H. Pieter, Swart, Joost F., van Royen‐Kerkhof, Annet, el Idrissi, Ayman, Leek, Arjen P., de Jager, Wilco, de Groot, Mark C. H., Haitjema, Saskia, Holzinger, Dirk, Foell, Dirk, van Loosdregt, Jorg, Wulffraat, Nico M., de Roock, Sytze, Vastert, Sebastiaan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Pediatric Rheumatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617757/
https://www.ncbi.nlm.nih.gov/pubmed/30848528
http://dx.doi.org/10.1002/art.40865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617757/
https://www.ncbi.nlm.nih.gov/pubmed/30848528
http://dx.doi.org/10.1002/art.40865

Ejemplares similares